Citations

Clear

6273 citation(s) found for "To, Andrew".

Olfactory decline in aging: longitudinal trajectories and associations with cognitive decline and postmortem neuropathology
Tremblay, Cécilia , Driver-Dunckley, Erika, Alasmar, Zaki , Serrano, Geidy E, Shill, Holly A. , Mehta, SH, Ho, Andrew, Fereshtehnejad, Seyed-Mohammad , Shprecher, David, Lorenzini, Ileana , Belden, Christine M. , Atri, Alireza, Adler, Charles H, Beach, Thomas G, Dadar, Mahsa, Zeighami, Yashar, Choudhury, Parichita , Driver‐Dunckley, Erika , Serrano, Geidy E. , Mehta, Shyamal H. , Ho, Andrew H, Shprecher, David , Atri, A., Adler, Charles H. , Beach, Thomas G. , Dadar, Mahsa , Zeighami, Yashar

Mayo Clinic

No container title available | April 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.27.26351817 | PMID 42094133 Get It

Abstract Importance Decline in olfactory function may be used as a predictor of cognitive decline, to enhance early detection models, improve risk stratification, and enable early intervention. Objective To assess the longitudinal association between olfactory decline, cognitive decline, and postmortem neuropathology. Design, setting and participants Retrospective longitudinal analysis with clinicopathological correlations of a prospective population-based cohort study using data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and its Brain and Body Donation Program. Participants included cognitively unimpaired individuals without parkinsonism that converted to mild cognitive impairment (MCI) and/or dementia or remained cognitively stable. Main Outcomes and Measures longitudinal change in olfaction, neuropsychiatric symptoms, motor function and memory, conversion to MCI/dementia, postmortem neuropathology Results Over a mean follow-up period of 7.7 ± 5.4 years, out of 922 participants who were cognitively unimpaired at the first cognitive conference, 643 remained cognitively unimpaired, 279 converted to MCI, and 82 developed dementia. Of these, 633 individuals had at least 2 olfactory tests. Converters showed reduced olfactory function (t=-12.6, p <0.0001), faster progression in neuropsychiatric symptom burden (t=3.42, p < 0.001), and faster decline in memory (t= -7.33, p <0.0001) prior to conversion while no significant differences were observed in motor scores between converters and non-converters. Using ROC analysis, olfactory decline, increased neuropsychiatric symptom burden, as well as motor and memory decline predicted conversion to MCI with a consistent accuracy of ∼ 70% up to 5 years before conversion, while UPSIT alone had an accuracy of ∼ 60%. Longitudinal decline in olfaction was associated with a higher burden of a-synuclein (t= -8.21, p <0.0005), tau tangle (t= -2.66, p < 0.01) and amyloid plaque burden (t= -2.85, p < 0.005) and a faster decline over time was associated with a higher burden of tau (t=5.66, p<0.0001). Conclusions and Relevance A reduction in olfactory identification ability is observed up to a decade prior to conversion to MCI and is associated with underlying burden of neuropathology markers, underscoring the value of incorporating olfactory testing in cognitively unimpaired individuals to identify those at-risk of future cognitive decline.
Towards a tool to discriminate between pain mechanistic descriptors: expert ranking of clinical features and allocation of weights using a forced choice paradigm
Shraim, Muath A. , Sterling, Michele, Arendt-Nielsen, Lars, Bačkonja, Miroslav , Baron, Ralf, Blechschmidt, Vivian , Clauw, Daniel J, Cohen, Milton , Coombes, Brooke K. , Elsenbruch, Sigrid, Gilron, Ian , Kato, Fusao, Madden, Victoria J, Nijs, Jo, Reis, Felipe J J, Rice, Andrew C, Ringkamp, Matthias , Irani, Anushka, Hodges, Paul W, Clauw, Daniel J. , Irani, Anushka , Arendt‐Nielsen, Lars , Hodges, Paul W , Irani, Anushka , Sterling, Michele M. , Sluka, Kathleen A. , Baron, Ralf , Elsenbruch, Sigrid , Harris, Richard Edmund , Jones, Lester Edmund , Kapreli, Eleni , Kato, Fusao , Kosek, Eva , Madden, Victoria J. , Schmid, Annina B , Irani, Anushka, Veasley, Christin

Mayo Clinic

Pain | April 28, 2026 | Volume: 167 | Issue: 7 | Pages: 1669-1682

10.1097/j.pain.0000000000003979 | PMID 42048572 Get It

Abstract Pain treatments have modest effects. Health outcomes might be improved if treatments are matched to mechanisms underlying the persistence and biopsychosocial impact of an individual's pain. The International Association for the Study of Pain (IASP) defines 3 mechanistic pain descriptors presumed to involve different mechanisms—nociceptive, neuropathic, and nociplastic. Although treatments to address each descriptor have been proposed, there is no consensus on how to assign descriptors to clinical presentations. A recent consensus identified candidate clinical features to discriminate between descriptors in clinical practice and research. These need refinement to progress towards a tool. This study aimed to determine the rank and relative weight of identified clinical features to aid discrimination between mechanistic pain descriptors. Candidate clinical features (n = 196) were refined by the IASP Terminology Task Force to converge similar and remove redundant features. The Task Force (n = 24) and an expert panel (n = 39) ranked features using 1000minds conjoint analysis software and assigned weights based on discrete pairwise choices. Participants nominated from pairs of scenarios, which most likely indicated that pain aligned predominantly to a descriptor. Highest ranked features for neuropathic and nociplastic pain were aligned with IASP Clinical Criteria. Criteria for nociceptive pain have not been established. A ranked list of features shared by 2 mechanisms (indicating mixed mechanisms) was also identified. This study identified expert consensus on the highest ranked clinical features with potential to discriminate between pain descriptors, reflective of different underlying mechanisms. This study extends current frameworks by identifying and refining key discriminators for future operationalisation and validation.
Smarter FoCUS: AI-guided focused cardiac ultrasound enables novice detection of left ventricular dysfunction
Kane, Conor J. , Borgeson, Jordan, Greason, Christie, Malins, Jeffrey G. , Anisuzzaman, D M, Tsaban, Gal, Schonfeld, Daniel, Jackson, John I. , Wood, Julia, Lee, Eunjung, Friedman, P A, Kane, Garvan C, Oh, J, Pellikka, Patricia A, Poterucha, Timothy J. , Rosenbaum, Andrew, Attia, Zachi I, Thaden, Jeremy J. , Bird, Jared, Friedman, Paul A , Lopez-Jimenez, Francisco , Poterucha, Timothy Joseph , Bird, Jared G , Kane, Conor, Borgeson, Jordan, Greason, Christie, Anisuzzaman, DM , Tsaban, Gal , Schonfeld, Daniel Andres, Lee, E, Naser, Jwan A. , Friedman, Paul A. , López-Jiménez, Francisco , Kane, Garvan C. , Pellikka, Patricia A. , Attia, Zachi I. , Pislaru, Sorin V.

Mayo Clinic

European Heart Journal - Digital Health | April 27, 2026 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/ehjdh/ztag066 | PMID 42169733 Get It

Abstract Aims Heart failure is prevalent; however, there is no cost-effective screening option. Against formal echocardiography, we assessed the diagnostic performance of focused cardiac ultrasound (FoCUS), performed by novice users guided and interpreted by artificial intelligence (AI) for the assessment of left ventricular ejection fraction (LVEF). Methods and results We prospectively enrolled 496 adults referred for diagnostic echocardiography. Novice operators (without clinical or imaging experience) underwent a 4-h imaging workshop, then performed FoCUS using a point-of-care device (Philips Lumify) utilizing real-time AI-image guidance (UltraSight). Images were assessed by AI-image interpretation software (Mayo Clinic), and two expert blinded echocardiologists. Median age was 67, 39% female, and body mass index range 17–56 kg/m2. Forty-one subjects (8.3%) exhibited moderate or greater LV dilatation and 28 (5.6%) had LVEF &lt;40%. The median scan time was 4 min (IQR 3–5). Adequate views were achieved in 95.0% and 97.4% of subjects for AI interpretation and expert analysis, respectively. A two-step diagnostic screening process for low EF in which only abnormal AI reads or uninterpretable scans were reviewed by experts (15.1%) had a sensitivity 96.2%, specificity 95.4%, PPV 54.3%, and NPV 99.8%. A subsequent prospective validation study of 344 subjects demonstrated similar results (sensitivity 100%, specificity 99.4%). Conclusion In this early feasibility investigation, AI-guidance technology embedded on a handheld device, enabled novice users without clinical or imaging experience to acquire sufficient quality images to accurately assess LVEF with minimal training. The technology evaluated in this study may hold promise for AI-guidance and interpretation to facilitate low-cost screening for cardiac dysfunction.
Drug Repurposing for Lung Disease: Mechanistic Rationale, Clinical Evidence, and the Path Forward
Bhatt, Shubhang K, GYIMAH, CLAUDIA, Kaul, Bhavika , Limper, Andrew, Dempsey, Timothy, Limper, Andrew H. , Limper, Andrew H , Bhatt, S, Gyimah, Claudia , Johannson, Kerri A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag216 | PMID 42089679 Get It

Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Eliashiv, Dawn , Rao, Vikram R. , Jobst, Barbara C. , Szaflarski, Jerzy P. , Rolston, John D., Kaye, Lesley , Bullinger, Katie L. , Dugan, Patricia , Burdette, David E. , Peters, Angela , Sheikh, Atif, Haas, Kevin F., Mnatsakanyan, Lilit , Bensalem‐Owen, Meriem, Study, for the RNS System PAS, Doherty, Michael J., Razavi, Babak, Fisher, Tiffany , Modur, Pradeep N., Constantino, Tawnya, Salanova, Vicenta , Taraschenko, Olga , Rivera‐Cruz, Angélica , Balabanov, Antoaneta, Aboumatar, Sami, Fried, Itzhak , Drees, Cornelia , Shin, Hae Won, Jaisani, Zeenat , Maciver, Stephanie , Patra, Sanjay , Chang, Edward F. , Gwinn, Ryder, Stoub, Travis , Crabtree, Tami , Seale, Cairn G. , McFadden, Sharon C. , Norman, Jacob F. , Johnson, Lise, Elisevich, Kort, Peng, Emory, Mazumder, Rajashi, Jennings, Tara, Esparza, Melissa Johnston, Harid, Nitish, Farooque, Pue , Hirsch, Lawrence, Gerrard, Jason, Wabulya, Angela , Riley, Kristen, Pati, Sandipan, Johnson, Jessica, Kirchoffer, Kaitlyn, Bamps, Yvan , Rolston, John D. , Rolston, John D , Kaye, Lesley C , Ganguly, Taneeta Mindy , Bullinger, Katie , Dugan, Patricia C , Burdette, David E , Peters, Angela Y , Sheikh, Atif , Haas, Kevin F , Nair, Dileep R , Mnatsakanyan, Lilit , Quraishi, Imran H , Bensalem-Owen, Meriem K , Doherty, Michael J , Razavi, Babak , Fisher, Tiffany L. , Skidmore, Christopher , Modur, Pradeep N , Constantino, Tawnya M , Cole, Andrew J , Taraschenko, Olga , Rivera-Cruz, Angelica , Wheless, James W , Tandon, Nitin , Balabanov, Antoaneta , Aboumatar, Sami , Fried, Itzhak , Drees, Cornelia , Shin, Hae Won , Jaisani, Zeenat , MacIver, Stephanie E , Patra, Sanjay E , Chang, Edward F , Willie, Jon T , Gwinn, Ryder , Stoub, Travis , Stern, John M , Crabtree, Tami , McFadden, Sharon C , Norman, Jacob F , Johnson, Lise , Morrell, Martha J , Jobst, Barbara , Rao, Vikram R , Ganguly, Taneeta M. , Nair, Dileep , Skidmore, Christopher , Cole, Andrew J. , Wheless, James W. , Tandon, Nitin , Gwinn, Ryder P. , Stern, John M. , Morrell, Martha J. , Pellinen, Jacob , Herlopian, Aline , Sivaraju, Adithya , Damisah, Eyiyemisi C. , Gerrard, Jason L. , Bentley, J. Nicole , Pati, Sandipan Bankim Behari

Mayo Clinic

Neurology | April 24, 2026 | Volume: 106 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214875 | PMID 42030518 Get It

Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
Sentana‐Lledo, Daniel , Rami, Avina , Zhong, Caiwei , Muniz, Miguel, Xie, W., Tchitchkan, Elizabeth , Stoltenberg, Hailey, Riaz, Irbaz Bin , Wolanski, Andrew, Ritzer, Jolivette, Jacene, Heather A. , Ravi, Praful , Xie, Wanling , Muniz, Miguel , Xie, Wanling , Jacene, Heather A , Schaffer, Kerry , Childs, Daniel S , Ravi, Praful , Riaz, Irbaz B , Rami, Avina , Childs, Daniel S.

Mayo Clinic

JCO Oncology Practice | April 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-01161 | PMID 42030508 Get It

PURPOSE 177Lu-PSMA-617 (LuPSMA) is an approved prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy for men with metastatic castration-resistant prostate cancer (mCRPC). Older patients, particularly octogenarians, represent a substantial proportion of men with mCRPC but have been traditionally underrepresented in key registrational trials of LuPSMA. METHODS This retrospective multi-institutional study evaluated patients age 80 years and older with mCRPC after chemotherapy treated with ≥1 cycle of LuPSMA from August 2022 to December 2024. Clinical and demographic data were abstracted from electronic medical records. Outcomes included prostate specific antigen (PSA) response (PSA50 and PSA90), progression-free survival (PFS), overall survival (OS), and toxicities. Kaplan-Meier methods estimated PFS/OS; descriptive statistics summarized baseline and safety data. RESULTS Ninety-five patients (median age, 83 years) were included, of whom 36 (38%) and 21 (22%) had a history of cardiac disease or chronic kidney disease, respectively. Median follow-up was 24.1 months (IQR, 6.7-28.1). Patients received a median of five cycles of LuPSMA. Fifty-two (57%) and 21 (23%) patients achieved a PSA50 and PSA90, respectively. Median PFS and OS were 7.3 months (95% CI, 6.4 to 8.7) and 13.5 months (95% CI, 9.7 to 18.8), respectively. Grade ≥3 hematologic toxicities included anemia (n = 19; 20%) and thrombocytopenia (n = 4, 4%); grade ≥3 acute kidney injury occurred in one patient. Fourteen (15%) patients had dose delays, seven (7%) required reductions, and 10 (11%) discontinued therapy due to toxicity. Thirty-seven patients (39%) were hospitalized during therapy, with intensive care unit-level care required in two patients (2%), and there was one treatment-related death. CONCLUSION LuPSMA had comparable outcomes in octogenarians with mCRPC to patients on registrational trials, although 2/5 of patients required hospitalization during therapy. These findings support the feasibility and efficacy of LuPSMA in well-selected older men with mCRPC and suggest a role for closer monitoring of older patients.
Outcomes with transcatheter aortic valve replacement for aortic stenosis in rheumatoid arthritis: an observational study
Ramadan, Adham, Doma, Mohamed, Mahmoud, Ahmed K, Atta, Raneem, Elgendy, Islam Y, Goldsweig, Andrew M. , Elgendy, Islam Y. , Doma, Mohamed , Doma, Mohamed , Goldsweig, Andrew M , Elgendy, Islam Y , Ramadan, Adham, Kamel, Ibrahim, Félix, Iuri Ferreira , Mahmoud, Ahmed K

Mayo Clinic

Rheumatology | April 24, 2026 | Volume: 65 | Issue: 5 | Pages: No page available

10.1093/rheumatology/keag234 | PMID 42049908 Get It

Abstract Objective To evaluate the short- and long-term clinical outcomes of transcatheter aortic valve replacement (TAVR) among participants with RA and aortic stenosis compared with those without RA, using real-world data from a large multicentre registry. Methods Using the TriNetX Research Network, participants with aortic stenosis undergoing TAVR with (RA+) vs without (RA−) RA were identified. Odds ratios (ORs) with 95% CIs estimated 30-day all-cause mortality, permanent pacemaker implantation, ischaemic stroke, acute kidney injury, myocardial infarction, cardiogenic shock, major vascular complications, and major or life-threatening bleeding were evaluated. Five-year outcomes included all-cause mortality, ischaemic stroke, myocardial infarction and all-cause hospitalization. Cox regression was used to estimate hazard ratios (HRs) with 95% CIs. Results A total of 1414 RA+ (4.3%) and 39 004 RA− participants were eligible. After matching, 1374 were included in each cohort. At 30 days, outcomes did not differ between RA+ and RA− groups; mortality was 2.0% vs 1.5% (OR 1.29; 95% CI 0.73–2.29), with no significant differences in other endpoints. Over 5 years, mortality was 23.8% vs 20.5% (OR 1.12; 95% CI 0.97–1.31), and stroke, myocardial infarction and hospitalization were similar; HRs were concordant with OR estimates. In sex-based analyses of RA patients, outcomes did not differ by sex. Conclusion In this large observational study, TAVR was not associated with excess short- or long-term risk in patients with RA. These findings support TAVR as a safe therapeutic option in RA patients with aortic stenosis.
Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data
Goel, Utkarsh , Dragomirescu, Catalin , Zanwar, Saurabh , Cassano, Rafaella Cassano, Cicero, Kara I. , Cowan, Andrew J., Banerjee, Rahul, Anwer, Faiz , Khouri, Jack , Cowan, Andrew J , Anwer, Faiz , Cowan, Andrew J. , Banerjee, Rahul , Dima, Danai

Mayo Clinic

British Journal of Haematology | April 23, 2026 | Volume: 208 | Issue: 6 | Pages: 2134-2142

10.1111/bjh.70490 | PMID 42023513 Get It

Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front‐line therapy. In this study, we combined data from three Center for International Blood and Marrow Transplant Research studies (MM18‐02, MM19‐01 and MM20‐03). We included patients who received front‐line AHSCT between 2008 and 2018 and had progression <12 (FHR12, n = 465), <18 (FHR18, n = 672) or <24 months (FHR24, n = 853) after AHSCT. We classified induction therapy as standard lenalidomide‐containing triplets (bortezomib, lenalidomide, dexamethasone [VRD]/carfilzomib, lenalidomide, dexamethasone [KRD]) versus other (bortezomib, thalidomide, dexamethasone [VTD]/bortezomib, cyclophosphamide, dexamethasone [VCD]/bortezomib, dexamethasone [VD]/lenalidomide, dexamethasone [RD]) and studied the impact of front‐line therapy on post‐FHR overall survival (OS). In the FHR12 cohort (follow‐up 48 months), the OS after VRD/KRD ( n = 238) was 21 versus 17 months with other regimens ( n = 227, hazard ratio [HR] = 1.2, 95% confidence interval [CI]: 0.6–1.06). In a multivariable model, the HR for OS was 0.94 (95% CI: 0.7–1.3, p = 0.69) for VRD/KRD versus other regimens. There was no significant interaction between type of first‐line (1L) therapy and time from 1L AHSCT to first relapse in predicting OS. Similar results were seen for FHR18 and FHR24. FHRMM remains a negative prognostic factor irrespective of front‐line therapy and warrants consideration of T‐cell engagers' second‐line therapy.
Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia
Zhou, Lu, Cao, Andrew , Zhu, Wen , Villalobos-García, Daniel, Marchan, Marisela Gamez, Curtis, Brian R. , Rauova, Lubica , Poncz, Mortimer, Aster, R D, Padmanabhan, Anand , Wang, Demin , Wen, Renren , Zhou, Lu , Curtis, Brian , Padmanabhan, Anand , Wang, Demin , Zhou, Lu, Marchan, Marisela, Poncz, Mortimer , Aster, RichardbH., Zhou, Lu

Mayo Clinic

Blood | April 21, 2026 | Volume: 148 | Issue: 1 | Pages: 115-129

10.1182/blood.2025032317 | PMID 42013023 Get It

Abstract The hallmark of heparin-induced thrombocytopenia (HIT) is the presence of immunoglobulin G (IgG) antibodies against platelet factor 4/heparin (PF4/H) complexes, typically detected by PF4/H enzyme-linked immunosorbent assay (ELISA); thus, negative ELISA results are commonly used to exclude this diagnosis. Here, we report a prevalent yet previously unrecognized subset of antibodies that are undetectable by PF4/H ELISA (ELISA−) but activate platelets in the PF4-dependent P-selectin expression assay (PEA+). In 11 patients with clinically confirmed HIT who tested positive in both PF4/H ELISA and platelet activation assays, ELISA−PEA+ antibodies accounted for 65% ± 19% of total platelet-activating IgG activity and coexisted with ELISA+PEA+ antibodies. Consistent with this finding, single-cell cloning from 7 patients with HIT identified 23 PEA+ antibody-producing B-cell clones, of which 17 were ELISA−, outnumbering the ELISA+ clones. Functionally, ELISA−PEA+ antibodies closely resembled ELISA+PEA+ antibodies: platelet binding and activation required exogenous PF4 and were inhibited by FcγRIIA blockade, high-dose heparin, or Fab fragments made from ELISA+PEA+ antibodies. Importantly, these antibodies induced thrombocytopenia in a humanized mouse model of HIT. Despite lacking PF4/H reactivity in ELISAs, they recognize PF4 on platelets and showed no appreciable binding to neutrophil-activating peptide-2, interleukin-8, or PF4 alone. Structurally, these antibodies were heterogeneous, with a subset sharing heavy-chain features with ELISA+PEA+ antibodies. Collectively, our findings demonstrate that ELISA−PEA+ antibodies are a common, previously unrecognized feature of HIT, with functional relevance, supporting the possibility that they play an important, perhaps even central, role in HIT pathogenesis. Defining their prevalence, kinetics, and clinical impact deserves high priority for further investigation.
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer
Makovec, Allison , Gustafson, Ava, Gandhi, N., Rampalli, Swati , Arafa, Ali T. , Elliott, Andrew , Smith, Norm, Felices, Martin , Kennedy, Philippa R. , Shenderov, Eugene , Heath, Elisabeth I. , Zorko, Nicholas A. , Shi, Xiaolei , McKay, Rana R. , Hwang, Justin H. , Gandhi, Nishant , Gustafson, Ava P , Gandhi, Nishant , Smith, Norm D. , Patnaik, Akash , Narayan, Vivek , Heath, Elisabeth I , Zorko, Nicholas A , Shi, Xiaolei , Antonarakis, Emmanuel S , McKay, Rana R , Hwang, Justin H , Arafa, Ali , Elliott, Andrew , Makovec, Allison , Shenderov, Eugene , Patnaik, Akash , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | April 21, 2026 | Volume: 32 | Issue: 15 | Pages: 3381-3394

10.1158/1078-0432.ccr-26-0322 | PMID 42012455 Get It

Abstract Purpose: B7-H3 (CD276) represents a promising therapeutic target tested in high-risk localized and treatment-refractory metastatic prostate cancer. To guide therapeutic development and treatment strategies, we examined prostate tumors and evaluated expression, molecular features, and overall survival (OS), accounting for tissue site, hormone sensitivity status, and race. Experimental Design: A total of 8,157 prostate cancer samples with paired DNA/RNA were analyzed based on annotations by tissue site, self-reported race, and disease state: hormone-sensitive prostate cancer (HSPC), castration-resistant prostate cancer (CRPC), or neuroendocrine prostate cancer (NEPC). Expression quartiles were B7-H3–high (&gt;75th percentile) or B7-H3–low (&lt;25th percentile). The OS was evaluated using Kaplan–Meier and Cox proportional hazards models. Results: B7-H3 expression was broadly maintained but varied by tumor site, hormone sensitivity status, and race. High expression aligned with AR-associated transcription factors (HOXB13 and FOXA1), AR-associated pathogenic dysregulations (AR-V7, SPOP, FOXA1, and TMPRSS2:ERG fusions), and actionable surface antigens (TROP2 and NECTIN-4). Weak correlations were found for lineage-plastic program regulators (EZH2, SOX2, and ASCL1) and NEPC-associated surface antigens (DLL3 and CEACAM5). High B7-H3 expression in primary tumors and HSPCs portended adverse OS [hazard ratio (HR), 1.342 and 1.30; confidence interval (CI), 1.19–1.512 and 1.15–1.46; q &lt; 0.0001] although it was favorable in metastatic tumors (HR, 0.823; CI, 0.719–0.942; q = 0.0048). No significant differences in OS were observed among CRPCs and NEPCs, although OS varied by race, with the poorest survival in Asian/Pacific Islander patients with metastatic prostate cancer (HR, 3.72; CI, 1.49–9.29; q = 0.012). Conclusions: Maintained B7-H3 expression in various prostate cancer settings supports its viability as a target. The associations with AR-related molecular factors, surface antigens, and investigative targets for cell therapy or antibody–drug conjugates suggest potential dual-targeting strategies. See related article by Sharma et al., p. 3365